Management of Obesity in Patients with Peripheral Arterial Disease

European Journal of Vascular and Endovascular Surgery

Volumn 34, Issue 5, 2007, Pages 576-582

  Giusti, V ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Body fat distribution; Cardiovascular risk factors; Obesity; Obesity treatment

Indexed keywords

DEXFENFLURAMINE; FENFLURAMINE; FLUOXETINE; PHENYLPROPANOLAMINE; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ARTERY DISEASE; ARTICLE; BARIATRIC SURGERY; BEHAVIOR MODIFICATION; CLINICAL TRIAL; DEFECATION DISORDER; DEFECATION URGENCY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EATING DISORDER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LOW CALORY DIET; LOW FAT DIET; OBESITY; OUTPATIENT CARE; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN DIET; RISK FACTOR; ROUX Y ANASTOMOSIS; STOMACH BYPASS; TACHYCARDIA; THERAPY EFFECT; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; BARIATRIC SURGERY; BODY COMPOSITION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; HUMANS; LIFE STYLE; OBESITY; PERIPHERAL VASCULAR DISEASES; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34848894561     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2007.05.005     Document Type: Article

References (54)

1. Wyatt S.B., Winters K.P., and Dubbert P.M. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci 331 (2006) 166-174
2. Groves T. Pandemic obesity in Europe. BMJ 333 (2006) 1081
3. Deitel M. The obesity epidemic. Obes Surg 16 (2006) 377-378
4. Bradley D.W. The epidemic of overweight and obesity: a challenge to medicine, public health and public policy. N C Med J 67 (2006) 268-272
5. Thompson D., Edelsberg J., Colditz G.A., Bird A.P., and Oster G. Lifetime health and economic consequences of obesity. Arch Intern Med 159 (1999) 2177-2183
6. Gilden Tsai A., and Wadden T.A. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity (Silver Spring) 14 (2006) 1283-1293
7. Delinsky S.S., Latner J.D., and Wilson G.T. Binge eating and weight loss in a self-help behavior modification program. Obesity (Silver Spring) 14 (2006) 1244-1249
8. Douketis J.D., Macie C., Thabane L., and Williamson D.F. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 29 (2005) 1153-1167
9. Norris S.L., Zhang X., Avenell A., Gregg E., Schmid C.H., Kim C., et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 164 (2004) 1395-1404
10. Ayyad C., and Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 1 (2000) 113-119
11. Kern P.A., Trozzolino L., Wolfe G., and Purdy L. Combined use of behavior modification and very low-calorie diet in weight loss and weight maintenance. Am J Med Sci 307 (1994) 325-328
12. Karlsson J., Taft C., Ryden A., Sjostrom L., and Sullivan M. Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. Int J Obes (Lond) (2007)
13. Dalle Grave R., Calugi S., Magri F., Cuzzolaro M., Dall'aglio E., Lucchin L., et al. Weight loss expectations in obese patients seeking treatment at medical centers. Obes Res 12 (2004) 2005-2012
14. Giusti V., Suter M., Heraief E., Gaillard R.C., and Burckhardt P. Rising role of obesity surgery caused by increase of morbid obesity, failure of conventional treatments and unrealistic expectations: trends from 1997 to 2001. Obes Surg 13 (2003) 693-698
15. Snow V., Barry P., Fitterman N., Qaseem A., and Weiss K. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 142 (2005) 525-531
16. Chul Sung K., Ryu S., and Reaven G.M. Relationship between obesity and several cardiovascular disease risk factors in apparently healthy Korean individuals: comparison of body mass index and waist circumference. Metabolism 56 (2007) 297-303
17. Wannamethee S.G., Shaper A.G., Morris R.W., and Whincup P.H. Measures of adiposity in the identification of metabolic abnormalities in elderly men. Am J Clin Nutr 81 (2005) 1313-1321
18. Goodpaster B.H., Krishnaswami S., Harris T.B., Katsiaras A., Kritchevsky S.B., Simonsick E.M., et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med 165 (2005) 777-783
19. Smith Jr. S.C., and Haslam D. Abdominal obesity, waist circumference and cardio-metabolic risk: awareness among primary care physicians, the general population and patients at risk-the Shape of the Nations survey. Curr Med Res Opin 23 (2007) 29-47
20. Cabrera M.A., Gebara O.C., Diament J., Nussbacher A., Rosano G., and Wajngarten M. Metabolic syndrome, abdominal obesity, and cardiovascular risk in elderly women. Int J Cardiol 114 (2007) 224-229
21. Berg A.H., and Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96 (2005) 939-949
22. Ritchie S.A., and Connell J.M. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 17 (2007) 319-326
23. Moller D.E., and Kaufman K.D. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 56 (2005) 45-62
24. Pouliot M.C., Despres J.P., Lemieux S., Moorjani S., Bouchard C., Tremblay A., et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 73 (1994) 460-468
25. Dansinger M.L., Gleason J.A., Griffith J.L., Selker H.P., and Schaefer E.J. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 293 (2005) 43-53
26. Halford J.C. Clinical pharmacotherapy for obesity: current drugs and those in advanced development. Curr Drug Targets 5 (2004) 637-646
27. Padwal R.S., and Majumdar S.R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369 (2007) 71-77
28. Zhi J., Melia A.T., Guerciolini R., Chung J., Kinberg J., Hauptman J.B., et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 56 (1994) 82-85
29. Padwal R., Kezouh A., Levine M., and Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond) (2007)
30. Kushner R.F., and Manzano H. Obesity pharmacology: past, present, and future. Curr Opin Gastroenterol 18 (2002) 213-220
31. Torgerson J.S., Hauptman J., Boldrin M.N., and Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27 (2004) 155-161
32. Kelley D.E., Kuller L.H., McKolanis T.M., Harper P., Mancino J., and Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 27 (2004) 33-40
33. Didangelos T.P., Thanopoulou A.K., Bousboulas S.H., Sambanis C.L., Athyros V.G., Spanou E.A., et al. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin 20 (2004) 1393-1401
34. Davidson M.H., Hauptman J., DiGirolamo M., Foreyt J.P., Halsted C.H., Heber D., et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281 (1999) 235-242
35. Walsh K.M., Leen E., and Lean M.E. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord 23 (1999) 1009-1015
36. Chaput J.P., and Tremblay A. Current and novel approaches to the drug therapy of obesity. Eur J Clin Pharmacol 62 (2006) 793-803
37. Ioannides-Demos L.L., Proietto J., and McNeil J.J. Pharmacotherapy for obesity. Drugs 65 (2005) 1391-1418
38. James W.P., Astrup A., Finer N., Hilsted J., Kopelman P., Rossner S., et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356 (2000) 2119-2125
39. Gursoy A., Erdogan M.F., Cin M.O., Cesur M., and Baskal N. Effect of sibutramine on blood pressure in patients with obesity and well-controlled hypertension or normotension. Endocr Pract 11 (2005) 308-312
40. Hanotin C., Thomas F., Jones S.P., Leutenegger E., and Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord 22 (1998) 32-38
41. Fernandez-Soto M.L., Gonzalez-Jimenez A., Barredo-Acedo F., Luna del Castillo J.D., and Escobar-Jimenez F. Comparison of fluoxetine and placebo in the treatment of obesity. Ann Nutr Metab 39 (1995) 159-163
42. Goldstein D.J., Rampey Jr. A.H., Dornseif B.E., Levine L.R., Potvin J.H., and Fludzinski L.A. Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obes Res 1 (1993) 92-98
43. Patel P.N., and Pathak R. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am J Health Syst Pharm 64 (2007) 481-489
44. Gadde K.M., and Allison D.B. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation 114 (2006) 974-984
45. Doyon C., Denis R.G., Baraboi E.D., Samson P., Lalonde J., Deshaies Y., et al. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 55 (2006) 3403-3410
46. Gelfand E.V., and Cannon C.P. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 47 (2006) 1919-1926
47. Despres J.P., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
48. Randall M.D., Kendall D.A., Bennett A.J., and O'Sullivan S.E. Rimonabant in obese patients with type 2 diabetes. Lancet 369 (2007) 555
49. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., and Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
50. Scheen A.J., Finer N., Hollander P., Jensen M.D., and Van Gaal L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 (2006) 1660-1672
51. O'Brien P.E., McPhail T., Chaston T.B., and Dixon J.B. Systematic review of medium-term weight loss after bariatric operations. Obes Surg 16 (2006) 1032-1040
52. Treadwell J.R., and Turkelson C.M. Systematic review of bariatric surgery. JAMA 293 (2005) 1726
53. Colquitt J., Clegg A., Loveman E., Royle P., and Sidhu M.K. Surgery for morbid obesity. Cochrane Database Syst Rev (2005) CD003641
54. Buchwald H., Avidor Y., Braunwald E., Jensen M.D., Pories W., Fahrbach K., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292 (2004) 1724-1737